Neurologist Samuel Hunter at the Advanced Neurosciences Institute in Franklin, Tennessee, noted in a February 14 article in the Financial Times that there is extensive patient data compiled on Gilenya and that the response of the EMA and Health Canada is likely an overreaction to recent deaths.